Key statistics
As of last trade, Appili Therapeutics Inc (APLIF:PKC) traded at 0.0255, 57.41% above the 52 week low of 0.0162 set on Feb 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.0255 |
---|---|
High | 0.0255 |
Low | 0.0255 |
Bid | -- |
Offer | -- |
Previous close | 0.0255 |
Average volume | 67.80k |
---|---|
Shares outstanding | 121.27m |
Free float | 121.19m |
P/E (TTM) | -- |
Market cap | 3.03m CAD |
EPS (TTM) | -0.0315 CAD |
Data delayed at least 15 minutes, as of Sep 19 2024 15:48 BST.
More ▼
Press releases
- Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025
- Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024
- Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic® Prostate Test, Targeting Early Detection in High-Risk Patients
- Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
- Aditxt’s Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™)
- Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics
- Aditxt Announces the Successful Passage of all Proposals at Recent Annual Shareholders’ Meeting, Setting the Stage for 2024 and 2025 Strategic Plans
- Aditxt Subsidiary Pearsanta Seeks Clinical Trial Translational Endpoints Research Award for Early Detection of Ovarian Cancer
- Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition
More ▼